台灣乳房醫學會 TBCS

Time Topic Speakers Moderator Meeting Room Abstract
08:35 - 08:40
Opening
陳芳銘
陳芳銘
 701B
08:40 - 09:20
Optimizing HR+ mBC treatment with ADCs
沈雯琪
 701B
09:20 - 10:00
Evolving Early Breast Cancer Care: Sustained Impact of CDK4/6 Inhibitors Across a Broader Stage II and Stage III HR+/HER2-Population
趙祖怡
 701B
10:00 - 10:10
Coffee Break
 701B
10:10 - 10:50
The Rising Burden of Breast Cancer in East Asia: the Role of Environmental and Endogenous Hormonal Factors
張金堅
 701B
10:50 - 11:30
Navigating Luminal Heterogeneity: Proteogenomic Subtyping for Targeted Treatment Strategies in Breast Cancer
侯明鋒
 701B
11:30 - 11:40
Real-World Effectiveness and Safety of Sacituzumab Govitecan in Taiwanese Patients with Metastatic Triple-Negative Breast Cancer: A Multicenter Retrospective Study
陳訓徹
 701B
11:40 - 11:50
Real-World Data on Treatment Efficacy in Patients With Residual HER2-Positive Early Breast Cancer
俞志誠
 701B
11:50 - 12:00
Real-World Efficacy and Safety of Oral Combination Metronomic Chemotherapy in Metastatic Breast Cancer -A Taiwanese Multicenter Study as First-Line Chemotherapy in the Post-CDK4/6 Inhibitor Setting
黃俊升
 701B
12:00 - 12:30
台灣乳房醫學會第十屆第二次會員大會
 701B